Search results
Showing 391 to 405 of 1003 results for public health medicine & health
Awaiting development Reference number: GID-TA11534 Expected publication date: TBC
Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]
Awaiting development Reference number: GID-TA11198 Expected publication date: TBC
Awaiting development Reference number: GID-TA11469 Expected publication date: TBC
Awaiting development Reference number: GID-TA11653 Expected publication date: TBC
Awaiting development Reference number: GID-TA11549 Expected publication date: TBC
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]
In development Reference number: GID-TA11160 Expected publication date: TBC
Awaiting development Reference number: GID-TA11758 Expected publication date: TBC
Awaiting development Reference number: GID-TA11686 Expected publication date: TBC
Awaiting development Reference number: GID-TA11222 Expected publication date: TBC
This manual explains the processes and methods used to develop and update NICE guidelines, the guidance that NICE develops covering topics across clinical care (in primary, secondary and community care settings), social care and public health. For more information on the other types of NICE guidance and advice (including technology appraisal guidance), see about NICE
Evidence summaries: unlicensed and off-label medicines – Integrated process statement (PMG14)
This integrated process statement has been produced to explain how 'Evidence summaries: unlicensed and off-label medicines' (ESUOMs) are developed. It provides an overview of the key process principles and describes all stages of development for ESUOMs
In development Reference number: GID-TA11694 Expected publication date: 10 February 2027
This guideline covers assessment, treatment, monitoring and inpatient care for children, young people and adults with eating disorders. It aims to improve the care people receive by detailing the most effective treatments for anorexia nervosa, binge eating disorder and bulimia nervosa.
Awaiting development Reference number: GID-TA11224 Expected publication date: TBC
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]
In development Reference number: GID-TA10966 Expected publication date: TBC